Budipine
Budipine is an Management of [Parkinson's disease#Medication|antiparkinson agent] marketed for the treatment of Parkinson's disease.
While its exact mechanism of action is not well characterized, it is believed to be an NMDA receptor antagonist, but also promoting the synthesis of dopamine.
Because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment.
It is an hERG potassium [channel blocker|blocker] and can produce long [QT syndrome] as a side effect.
Analogues include prodipine and medipine.
Synthesis
Budipine can be prepared from the 1-tert-butyl-4-piperidone directly by treatment with benzene in the presence triflic acid. This method of synthesis enables a 99% yield of product.File:Budipine synthesis.svg|class=skin-invert-image|thumb|center|500px| Synthesis:
4-Phenyl-1-t-butyl-4-piperidinol,
1-t-butyl-3-benzoyl-4-phenyl-4-piperidinol